vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and American Express (AXP). Click either name above to swap in a different company.
American Express is the larger business by last-quarter revenue ($18.9M vs $10.7M, roughly 1.8× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 15.7%, a 7.8% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 11.4%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -95.6%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
ABUS vs AXP — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $18.9M |
| Net Profit | $2.5M | $3.0M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | 15.7% |
| Revenue YoY | 522.2% | 11.4% |
| Net Profit YoY | 112.7% | 15.0% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $18.9M | ||
| Q4 25 | — | $10.9B | ||
| Q3 25 | — | $10.4B | ||
| Q2 25 | $10.7M | $10.3B | ||
| Q1 25 | — | $9.6B | ||
| Q4 24 | — | $10.0B | ||
| Q3 24 | — | $9.7B | ||
| Q2 24 | — | $9.8B |
| Q1 26 | — | $3.0M | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | $2.5M | $2.9B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $3.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 28.2% | ||
| Q3 25 | — | 36.7% | ||
| Q2 25 | 13.9% | 34.4% | ||
| Q1 25 | — | 34.6% | ||
| Q4 24 | — | 27.7% | ||
| Q3 24 | — | 33.0% | ||
| Q2 24 | — | 38.6% |
| Q1 26 | — | 15.7% | ||
| Q4 25 | — | 22.5% | ||
| Q3 25 | — | 27.9% | ||
| Q2 25 | 23.5% | 28.0% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 30.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.52 | ||
| Q3 25 | — | $4.14 | ||
| Q2 25 | $0.01 | $4.08 | ||
| Q1 25 | — | $3.64 | ||
| Q4 24 | — | $3.04 | ||
| Q3 24 | — | $3.49 | ||
| Q2 24 | — | $4.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | — |
| Total DebtLower is stronger | $0 | $60.4M |
| Stockholders' EquityBook value | $83.0M | $34.0M |
| Total Assets | $103.3M | $308.9M |
| Debt / EquityLower = less leverage | 0.00× | 1.78× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $742.0M | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $37.4M | $197.0M | ||
| Q1 25 | — | $261.0M | ||
| Q4 24 | — | $221.0M | ||
| Q3 24 | — | $120.0M | ||
| Q2 24 | — | $188.0M |
| Q1 26 | — | $60.4M | ||
| Q4 25 | — | $56.4B | ||
| Q3 25 | — | $57.8B | ||
| Q2 25 | $0 | $58.2B | ||
| Q1 25 | — | $51.2B | ||
| Q4 24 | — | $49.7B | ||
| Q3 24 | — | $53.5B | ||
| Q2 24 | — | $51.5B |
| Q1 26 | — | $34.0M | ||
| Q4 25 | — | $33.5B | ||
| Q3 25 | — | $32.4B | ||
| Q2 25 | $83.0M | $32.3B | ||
| Q1 25 | — | $31.2B | ||
| Q4 24 | — | $30.3B | ||
| Q3 24 | — | $29.7B | ||
| Q2 24 | — | $29.5B |
| Q1 26 | — | $308.9M | ||
| Q4 25 | — | $300.1B | ||
| Q3 25 | — | $297.6B | ||
| Q2 25 | $103.3M | $295.6B | ||
| Q1 25 | — | $282.2B | ||
| Q4 24 | — | $271.5B | ||
| Q3 24 | — | $271.0B | ||
| Q2 24 | — | $272.2B |
| Q1 26 | — | 1.78× | ||
| Q4 25 | — | 1.68× | ||
| Q3 25 | — | 1.78× | ||
| Q2 25 | 0.00× | 1.80× | ||
| Q1 25 | — | 1.64× | ||
| Q4 24 | — | 1.64× | ||
| Q3 24 | — | 1.80× | ||
| Q2 24 | — | 1.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $6.2B | ||
| Q2 25 | $-15.7M | $4.4B | ||
| Q1 25 | — | $4.8B | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | $-1.8B | ||
| Q2 24 | — | $4.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $5.6B | ||
| Q2 25 | — | $3.7B | ||
| Q1 25 | — | $4.3B | ||
| Q4 24 | — | $5.3B | ||
| Q3 24 | — | $-2.3B | ||
| Q2 24 | — | $4.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 45.0% | ||
| Q4 24 | — | 53.1% | ||
| Q3 24 | — | -23.3% | ||
| Q2 24 | — | 40.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 6.3% | ||
| Q2 25 | 0.0% | 6.0% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 5.0% | ||
| Q3 24 | — | 4.7% | ||
| Q2 24 | — | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.25× | ||
| Q3 25 | — | 2.15× | ||
| Q2 25 | -6.24× | 1.51× | ||
| Q1 25 | — | 1.84× | ||
| Q4 24 | — | 2.66× | ||
| Q3 24 | — | -0.72× | ||
| Q2 24 | — | 1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
